Literature DB >> 23352853

Production and characterization of chimeric anti-HLA monoclonal antibodies targeting public epitopes as tools for standardizations of the anti-HLA antibody detection.

Nicolas Congy-Jolivet1, Daniel Drocourt, Sylvain Portet, Gérard Tiraby, Antoine Blancher.   

Abstract

Two chimeric monoclonal antibodies (MoAbs) were designed with variable parts of the mouse antibodies W6/32 and F3.3, and the human constant parts C-gamma1 and C-kappa. These chimeric MoAbs are specific for HLA-class I and HLA-class II public epitopes, respectively. The anti-class I MoAb recognizes all HLA-class I tested so far, and the anti-class II MoAb recognize all HLA-DR, DP, and only DQ antigens of the DQ2 subgroup. These Moabs were used as positive controls in routine tests for the detection of IgG anti-HLA antibodies in the sera of patients (Luminex, flow cytometry, and complement-dependent lymphocytotoxicity assay: CD-LCT). In tests with the LABScreen MIX assay, serial dilutions of the two MoAbs have allowed to determine the thresholds of detection by the Boltzmann sigmoidal regression. The thresholds of detection in mean of fluorescence intensity (MFI) were 926 and 866 for the anti-class I MoAb and the anti-class II MoAb, respectively. The thresholds defined as mean+3SD of MFI values obtained with 30 negative control sera were 411 and 251 for the anti-class I beads and the anti-class II beads, respectively. For the daily validation of the anti-HLA IgG antibodies screening by LABScreen MIX we decided to use the positive control MoAbs at three concentrations (5, 50, and 500ng/ml) and we measured the repeatability (<10%) and reproducibility (<16%) of the method. Used as positive controls in tests with the LABScreen Single Antigen kit, the two MoAbs allowed to estimate daily the quality of beads coated with HLA antigens. The two anti HLA MoAbs were also used as positive control in the cross-match assay by flow cytometry or CD-LCT. In total these two chimeric anti-HLA-MoAbs, which have no equivalent so far, are valuable positive controls for the daily validations of most techniques used for the detection of anti-HLA antibodies according to the good practice guidelines for laboratories.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23352853     DOI: 10.1016/j.jim.2013.01.007

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  4 in total

1.  Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms.

Authors:  N M Valenzuela; K R Trinh; A Mulder; S L Morrison; E F Reed
Journal:  Am J Transplant       Date:  2015-02-03       Impact factor: 8.086

Review 2.  Genotyping Applications for Transplantation and Transfusion Management: The Emory Experience.

Authors:  Ross M Fasano; Harold Cliff Sullivan; Robert A Bray; Howard M Gebel; Erin K Meyer; Annie M Winkler; Cassandra D Josephson; Sean R Stowell; Alexander Sandy Duncan; John D Roback
Journal:  Arch Pathol Lab Med       Date:  2017-03       Impact factor: 5.534

3.  Recombinant human monoclonal HLA antibodies of different IgG subclasses recognising the same epitope: Excellent tools to study differential effects of donor-specific antibodies.

Authors:  Cynthia S M Kramer; Marry E I Franke-van Dijk; Ashley J Priddey; Tamás Pongrácz; Elena Gnudi; Helena Car; Gonca E Karahan; Els van Beelen; Chalana C C Zilvold-van den Oever; Hendrik J Rademaker; Noortje de Haan; Manfred Wuhrer; Vasilis Kosmoliaptsis; Paul W H I Parren; Arend Mulder; Dave L Roelen; Frans H J Claas; Sebastiaan Heidt
Journal:  HLA       Date:  2019-08-25       Impact factor: 4.513

4.  The oxygen carrier M101 alleviates complement activation, which may be beneficial for donor organ preservation.

Authors:  Bénédicte Puissant-Lubrano; Charlène Bouthemy; Nicolas Congy-Jolivet; Jean Milhes; Vincent Minville; Nassim Kamar; Leïla Demini; Franck Zal; Yves Renaudineau
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.